Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Daiichi Sankyo Inc.
Sponsor

Daiichi Sankyo Inc.

United States 211 Mount Airy Road, 07920-2311, United States

About the sponsor

Daiichi Sankyo Inc. funds a broad portfolio in HER2-positive, HER2-low, and HER2-expressing cancers, with work spanning breast cancer, gastric cancer, gastroesophageal junction adenocarcinoma, endometrial cancer, and ovarian cancer. Its studies also include treatment settings for metastatic solid tumors and locally advanced disease.

  • Trastuzumab deruxtecan in HER2-positive breast and gastric cancers
  • HER2-low and HER2 IHC 0 breast cancer
  • HER2-expressing ovarian and endometrial cancers

The sponsor also supports studies in adjuvant breast cancer and other HER2-driven malignancies across multiple tumour types.

About Specializations

Daiichi Sankyo Inc. runs clinical trials in conditions such as Non-small cell lung cancer, Ovarian cancer, Neoplasm, Transitional cell carcinoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

32 clinical trials

Oesophageal squamous cell carcinoma

Recruiting

Study of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Neoplasm malignant

Recruiting

A study of DS-3790A, rituximab, and epcoritamab in patients with blood cancers

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Daiichi Sankyo Inc.

HER2 positive endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer+1

Recruiting

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Transitional cell carcinoma

Recruiting

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Oesophageal cancer metastatic+3

Recruiting

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Daiichi Sankyo Inc.

Endometrial cancer+13

Recruiting

Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Small cell lung cancer extensive stage

Recruiting

Study of Ifinatamab Deruxtecan with Atezolizumab and Carboplatin for Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Daiichi Sankyo Inc.

Small cell lung cancer

Recruiting

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.

Colorectal cancer+5

Recruiting

Study on Long-Term Safety of Trastuzumab Deruxtecan for Patients with Advanced HER2-Positive or HER2-Mutated Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Neoplasm

Recruiting

Study of Patritumab Deruxtecan for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.